Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms
نویسندگان
چکیده
Does an expansion of patent scope induce more innovative effort by firms? We examine responses to the Japanese patent reforms of 1988. Interviews with practitioners and professional documents for patent agents suggest the reforms significantly expanded the scope of patent rights. However, econometric analysis using both Japanese and U.S. patent data on 307 Japanese firms finds no evidence of an increase in either R&D spending or innovative output which could be plausibly attributed to patent reform. The ordering of authors' names was determined by a coin toss. This project is part of the NBER project on Industrial Technology and Productivity, and we are grateful to the Alfred P. Sloan Foundation for its financial support of this project. Sakakibara gratefully acknowledges the financial support of the Center for International Business Education and Research at the UCLA Anderson Graduate School of Management. Branstetter thanks the Japan Foundation Center for Global Partnership for financial support. We would like to thank officials at the Japanese Patent Office, especially Masafumi Yamamoto and Shunichi Doi for detailed information on the Japanese patent system, Takao Oogiya for information on patenting by Japanese firms, and Yoshisue Tsunoda and Michiko Tanaka for their help in arranging interviews with Japanese companies. We are also grateful to the general managers of intellectual property departments at 10 major Japanese companies for sharing their insights. Akinori Yamaguchi and Tsuyoshi Kakita at the Japan Patent Information Organization provided us with detailed Japanese patent data. In addition, we would like to thank seminar participants, and anonymous referees for helpful discussions and comments. Branstetter wishes to thank Professor Yosuke Okada of Shinshu University for discussions which inspired this research project, and for providing valuable information about the evolution of the Japanese patent system. Kaoru Nabeshima, Heather Berry, and Tatsuo Ushijima provided excellent research assistance.
منابع مشابه
Working Paper No. 07-21 Business Method Patents for U.s. Financial Services
Nearly a decade after the Federal Circuit decision in State Street, patents on computerimplemented methods of doing business have become commonplace. To date, there is little evidence of any effect on the rate of innovation or R&D among firms in financial services. Indeed, measuring such effects presents difficult problems for researchers. We do know that some of these patents are successfully ...
متن کاملThe patent law Duchy of Grand Fenwick: a comment on The mouse that trolled: the long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer's research
This comment on The mouse that trolled by Tania Bubela, Saurabh Vishnubhakat, and Robert Cook-Deegan discusses the authors' description of how patents relating to the gene coding for a protein involved in Alzheimer's disease were obtained and used to sue scientific researchers, of how conflicts can arise among groups of researchers, and of how important research can be delayed or foregone by th...
متن کاملInnovation and Firm Value: An Investigation of the Changing Role of Patents and Firm Publications
How to measure R&D capabilities is a key concern for policymakers and practitioners alike. This paper examines the changing role of patents and firm publications as a signal of scientific and technical competence. We argue that recent patent reforms might have reduced the informational value of USPTO patents relative to EPO patents. Moreover, the global trend toward stronger patent enforcement ...
متن کاملMaking Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovati...
متن کاملPatent Trolling: Why Bio & Pharmaceuticals Are at Risk
Patent trolls—also known variously as non-practicing entities, patent assertion entities, and patent monetizers—are a top priority on legislative and regulatory reform agendas. In modern debates, however, the biopharmaceutical industry goes conspicuously unmentioned. Although the biopharmaceutical industry is paradigmatically centered on patents, conventional wisdom holds that it is largely unt...
متن کامل